Answers are grounded in this paper and cite their sources.
Case report shows sustained viral suppression in HIV patient with dolutegravir and lamivudine resistance, suggesting resilience of treatment. Integrase inhibitors play a crucial role in drug regimens.
Integrase strand transfer inhibitors (INSTIs) are recommended in most first-line HIV treatment regimens. We describe a participant in a clinical trial with transmitted INSTI resistance. The participant had no history of INSTI use and had no evidence of INSTI exposure prior to HIV acquisition. Treatment with tenofovir disoproxil fumarate, lamivudine (3TC), and dolutegravir (DTG) was started three weeks after HIV diagnosis. Viral suppression was achieved within a year and was sustained for >3 years on treatment. Retrospective HIV genotyping of a pre-treatment sample detected major resistance mutations in three drug classes, with predicted high-level resistance to DTG and 3TC. HIV phenotyping confirmed that the transmitted virus had DTG and 3TC resistance but retained susceptibility to DTG at higher drug concentrations. Pharmacologic testing indicated that the DTG concentrations observed in this case were sufficient to overcome the effects of two major baseline INSTI resistance mutations (G140S and Q148H).
No takes yet. Share an insight, caveat, or question.
Moore et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: